US Study: Nasal COVID Vaccine Shows Promise in Phase 1 Trial

Image credit: University of Georgia [via NBC News]

The Spin


Narrative A

Every development of a new, better vaccine is a step in the right direction. Three years into the pandemic, COVID is here to stay, which is why broader solutions like Blue Lake's are the way forward — chasing perpetual variants with targeted vaccines is no longer a viable option.

Narrative B

Broader solutions are certainly the goal, but nasal vaccines likely won't meet this. Immunity that comes from infection similarly enters the body through the respiratory tract but only offers a brief period of protection from infection, so nasal sprays would probably have the same impact. The antibodies created by nasal vaccines typically wane quicker than others.


Metaculus Prediction

© 2026 Improve the News Foundation. All rights reserved.Version 7.0.0

© 2026 Improve the News Foundation.

All rights reserved.

Version 7.0.0